Position Description

Provide legal assistance to employees in the legal department as well as across various functions of the company. Draft, review and negotiate contracts under attorney supervision. Prepare and coordinate documents for general legal matters, including but not limited, to general corporate governance matters, SEC disclosure, commercial compliance, regulatory, contract management and general business matters.  Maintain legal department systems, databases, records and files.

Responsibilities (include, but are not limited to):

  • Draft, review, negotiate and file various agreements
  • Maintain legal department systems, records, files and contract management system (CMS) as appropriate.
  • Maintain BOD and Committee documents including meeting minutes, materials, resolutions and related documents.
  • Participate in preparation of SEC filings and related activities.
  • Prepare, file and maintain documents related to FCPA, State Corporate Filings and other documents.
  • Use a wide range of legal or specialized knowledge to provide legal support services in an efficient and timely manner.
  • Research legal issues and engage in fact gathering and checking to provide support on all assigned legal matters.
  • Other job duties as assigned.


  • Paralegal Certification and 5+ years of legal department experience in the biotech/pharma, life sciences industry required.  Some law firm experience reviewing, analyzing and interpreting legal contracts and documents highly desirable.
  • Demonstrated ability to read, analyze and interpret contracts and legal documents and to effectively present information to business partners and management.
  • Exercise independent judgment regarding legal and contractual matters within broadly defined practices and policies.
  • Must have demonstrated and substantial expertise drafting, reviewing and negotiating legal contracts and documents, with a focus in the pharmaceutical/life sciences industry.
  • Demonstrated ability to work cross-functionally with employees, contractors and vendors at all levels within the organization.
  • General understanding of a broad range of corporate in-house legal matters.
  • Demonstrated proficiency using a variety of computer software, including MS Outlook, Word, Excel, Power Point as well as contract management and legal software applications.
  • Exceptionally strong interpersonal communications skills and a collaborative, service-oriented manner.
  • Strong problem-solving and analytical thinking skills.
  • Ability to meet multiple deadlines with a high degree of accuracy and efficiency.
  • Must have excellent attention to detail and exceptional organizational skills.
  • Self-motivated, requiring limited supervision and a desire to learn.

About AVEO:

The Company’s lead candidate is tivozanib, an oral, once-daily, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective, long half-life inhibitor of all three VEGF receptors, which AVEO is seeking to develop and commercialize in North America as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers. On June 1, 2020, the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for tivozanib as a treatment for relapsed or refractory RCC and assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2021. Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced RCC in the European Union plus Norway, New Zealand and Iceland. AVEO is leveraging or seeks to leverage partnerships to develop and commercialize its pipeline of products and product candidates, including tivozanib in oncology and other indications in various geographies, and ficlatuzumab (HGF MAb) in head and neck cancer and pancreatic cancer. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3 MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) drug candidates being developed for various oncology indications.

Tivozanib, ficlatuzumab, AV-203, AV-380 and AV-353 are investigational drugs and have not yet been approved by the U.S. Food and Drug Administration (FDA).

Tivozanib, ficlatuzumab, AV-203, AV-380 and AV-353 are investigational drugs and have not yet been approved by the U.S. Food and Drug Administration (FDA).